# Shandong Cancer Hospital and Institute: Phase 3 study in Newly Diagnosed Triple-negative Breast Cancer (852 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Shandong Cancer Hospital and Institute |
| Sponsor type | Academic and hospital |
| Study | A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer |
| NCT ID | NCT07869628 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Newly Diagnosed Triple-negative Breast Cancer |
| Intervention types | drug |
| Target enrollment | 852 |
| Posted | 2026-10-09 |
| Planned start | 2026-10-17 |
| Event | Newly registered study |
| Event date | 2026-10-09 |

## Why this score
- Phase 3: multi-site, larger budget.
- 852 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07869628). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.